



## Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference

April 28, 2022

### *Findings Provide New Insights into Genomic Underpinnings of Prostate and Bladder Cancers*

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 28, 2022-- [Veracyte, Inc.](#) (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder cancers will be presented at the American Urological Association Annual Meeting, taking place May 13-16, 2022, in New Orleans. The findings are derived from analyses of the Decipher GRID, a database that contains genomic profiling information from clinical samples used in the development and commercial application of the Decipher Prostate and Decipher Bladder tests.

"The data being presented at AUA 2022 highlight the transcriptional complexity of prostate and bladder cancers, knowledge that we hope can be used to better personalize therapy," said Elai Davicioni, Ph.D., Veracyte's medical director for Urology. "Importantly, these analyses also reinforce the value of our Decipher GRID database, which contains over 100,000 transcriptomes of prostate and bladder cancers, for urologic oncology researchers all around the world."

Following are details of the Decipher GRID abstracts accepted for poster presentation at the AUA 2022 meeting, which will be held at the Ernest N. Morial Convention Center:

**Date/Time:** May 13, 2022, 10:30-10:40 a.m. ET

**Title:** Molecular subtyping of >80,000 prostate cancer transcriptomes identifies four classes with distinct biological and clinical characteristics with implications for targeted therapies (#PD07-07)

**Presenter:** Adam B. Weiner, M.D., Northwestern University

**Location:** Room 245

**Date/Time:** May 13, 2022, 8:45-10:00 a.m. ET

**Title:** Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis (#MP06-02)

**Presenter:** Joep de Jong, M.S., Erasmus MC Cancer Institute

**Location:** Room 222

**Date/Time:** May 15, 2022, 1:00-2:15 p.m. ET

**Title:** Does Perioperative Testosterone Predict Post-Prostatectomy Genomic Risk Score? (#MP45-10)

**Presenter:** Mohammed Shahait, M.D., King Hussein Cancer Foundation and Center

**Location:** Room 225

### **About Veracyte**

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the ten most prevalent cancers as defined by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit [www.veracyte.com](http://www.veracyte.com) and follow the company on Twitter (@veracyte).

### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Decipher GRID database, and Decipher Prostate and Decipher Bladder tests. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "suggest," "may," "will" "prospective" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte's belief that its Decipher Prostate genomic classifier can help guide treatment among men with intermediate-risk prostate cancer. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 28, 2022 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at [www.veracyte.com](http://www.veracyte.com). These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HaliuDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, "Know by Design" and "More about You" are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220428006287/en/): <https://www.businesswire.com/news/home/20220428006287/en/>

### **Investors:**

[investors@veracyte.com](mailto:investors@veracyte.com)

619-393-1545

**Media:**

Tracy Morris

Vice President of Global Corporate Communications

[tracy.morris@veracyte.com](mailto:tracy.morris@veracyte.com)

650-380-4413

Source: Veracyte, Inc.